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1 These authors contributed equally to this work.A full-length cDNA encoding an anticoagulant peptide, named AduNAP4, was cloned and identiﬁed
from the human hookworm Ancylostoma duodenale. AduNAP4 has 104 amino acids including a pre-
dicted 23-residue signal peptide and shows 650% similarity with other known nematode anticoag-
ulant protein/peptide (NAP). AduNAP4 is extremely efﬁcient at prolonging the activated partial
thromboplastin time, and is an inhibitor of both fXa (Ki = 7.34 ± 1.74 nM) and fXIa
(Ki = 42.45 ± 3.25 nM). No fXIa inhibitor has previously been described from other blood-feeding ani-
mals. Our results suggest that hookworms have evolved a potent mechanism that interferes with
coagulation by inhibition of fXIa to facilitate its blood-feeding lifestyle.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian species have complicated mechanisms for prevent-
ing blood loss. The hemostatic system comprises platelets and coag-
ulation factors to stop bleeding from an injured blood vessel by
rapid formation of a ﬁbrin clot. The coagulation cascade is initiated
by the factor VIIa/tissue factor (fVIIa/TF) complex, which activates
fIX and fX. The small amounts of fXa activated during the initiation
phase convert prothrombin to thrombin, which ampliﬁes the coag-
ulation cascade by activation of the fV, fVIII, and fXI on the surface of
platelets. The feedback activation of fXI by thrombin is believed to
be very important for sustaining thrombin production. The fXIa
can activate additional fIXa to supplement what was initially acti-
vated by fVIIa/TF but limited by tissue factor pathway inhibitor.
Therefore activation of fXIa by thrombin results in more fXa, which
generates more thrombin and accelerates ﬁbrin formation [1–3].chemical Societies. Published by E
tein/peptide; aPTT, activated
; fVIIa/TF, factor VIIa/tissue
peptide; AcAP, AncylostomaHookworms are blood-feeding nematodes that inhabit the
small intestine of mammalian hosts, including humans, dogs and
cats. Upon attachment to the intestinal mucosa, hookworms feed
on blood and cause blood loss. An adult hookworm may cause up
to 0.2 ml blood loss per day [4,5], and is often a major cause of iron
deﬁciency anemia and protein malnutrition in the host [6,7]. Hu-
man hookworm infection, which is mostly caused by the two spe-
cies Ancylostoma duodenale and Necator americanus, is one of the
most common chronic infections of humans. It is estimated that
about 600 million people in the world are infected with hookworm
[8,9].
Like other blood-feeding invertebrates, such as leeches, ticks
and triatomine bugs [10–12], hookworms have evolved potent
mechanisms to counteract host hemostatic responses and facilitate
blood feeding. To date, several distinct antithrombotic molecules
have been isolated from the hookworm A. caninum [13–15], a com-
mon parasite of dogs, and A. ceylanicum [16], which infects dogs
and cats and can also infect humans, although it is not considered
a major human pathogen. Hookworm anticoagulant peptides, also
known as nematode anticoagulant proteins/peptides (NAPs), are
the major antihemostatic molecules found in hookworm
[13,14,16]. However, little is known about the antithrombotic mol-
ecule in A. duodenale or N. americanus.
NAPs can block the host coagulation cascade by inhibition of
fVIIa/TF, the initiator of coagulation, or fXa, the point of convergencelsevier B.V. All rights reserved.
W. Gan et al. / FEBS Letters 583 (2009) 1976–1980 1977of the extrinsic and intrinsic pathways [13,14,17]. In the present
study, we describe the identiﬁcation and characterization of an
anticoagulant peptide, AduNAP4, from the human hookworm A.
duodenale. AduNAP4 is an inhibitor of both fXa and fXIa. As a fXIa
inhibitor, AduNAP4 can interfere with the ampliﬁcation of the
coagulation cascade. To our knowledge, no inhibitory mechanism
of fXIa has been described from other blood-feeding animals. Our
results clearly suggest that the hookworm, A. duodenale has
evolved such a mechanism to facilitate blood feeding.2. Materials and methods
2.1. RNA extraction and cDNA synthesis
Total RNA was extracted from adult A. duodenale using an RNA-
fast 200 kit (FASTAgen, Shanghai, China), and the ﬁrst-strand cDNA
was synthesized from total RNA with a 30-Full RACE Core Set kit
(TakaRa, Dalian, China) according to the manufacturer’s
instructions.
2.2. Cloning of the full-length cDNA encoding AduNAP4
Rapid ampliﬁcation of 30 cDNA ends of AduNAP4 was carried
out using a 30-Full RACE Core Set kit. The forward primer AdP3-1
(50 TTGCGTATGCA/GAA/TG/TAC/A/TGGA 30) was designed, based
on the conserved sequences of the cDNA of AcAP5 (GenBank acces-
sion no. U30795), AcAP6 (U30794), AcAPc2 (U30793), AcAPc3
(AY232998), AcAPc4 (AY253915) and AceAP1 (AF399710). For
ampliﬁcation of the 50cDNA sequences, RT-PCR was performed
using forward primer SL1 (50 GGTTTAATTACCCAAGTTTGAG 30),
and reverse primer AdP-2 (50 CTTGTCTCTGTATAATCCGTC 30),
which was designed from the AduNAP4 30cDNA sequences. The
PCR conditions were 94 C for 5 min, followed by 30 cycles of
94 C for 30 s, 58 C for 40 s, and 72 C for 1 min, with a ﬁnal
10 min extension at 72 C. The ampliﬁed AduNAP4 cDNA were
cloned into pUCm-T vector (BBI, Canada) and sequenced using an
ABI 377 automated sequencer (Applied Biosystems, USA).
2.3. Sequence analysis
Lasergene software (DNASTAR Inc. USA) was used for ORF
searches and sequence analysis. Similarity searches of nucleotide
and deduced amino acid sequences were performed with BLAST
programs on the NCBI web site (http://www.ncbi.nlm.nih.gov). Se-
quence alignments and percentage identity were generated by
CLUSTAL W in the Lasergene software package. The signal peptide
was predicted by the SignalIP 3.0 program (http://www.cbs.dtu.dk/
services/signalP).
2.4. Expression and puriﬁcation of recombinant AduNAP4 in
Escherichia coli
The primer pair Ad4-1e (50 GTGGATCCAAATGTCCTACCGAT-
GAATGG 30) and Ad4-2e (50 CGAAGCTTATTTGGTTTCTGGTGCAAA
30) was used to amplify cDNA fragments encoding the mature
AduNAP4 protein. The PCR product was digested with BamHI/Hin-
dIII and ligated into the pET32a expression vector. The recombi-
nant plasmid pET32a/AduNAP4 was then transformed into E. coli
BL21 (DE3). Expression of recombinant protein was induced with
1 mM IPTG. Cells were harvested by centrifugation, and lysed by
sonication. The recombinant proteins were afﬁnity-puriﬁed using
Protino Ni-IDA Resin (Macherey-Nagel, Germany), desalted and
concentrated by ultraﬁltration Centrifugal Devices (Pall Co.,
USA). The purity and molecular weight of the proteins were eval-
uated by 12% SDS–PAGE. The pET32a empty vector was also trans-formed into E. coli BL21 (DE3), and the protein contained the
thioredoxin and histidine fusion tag alone was prepared for the
control.
2.5. Anticoagulation assays
Anticoagulant activity was determined by the activated partial
thromboplastin time (aPTT) and prothrombin time (PT) clotting as-
says [14,17]. For the aPTT assay, 10 ll puriﬁed protein at various
concentrations, or buffer alone, was added to microtiter wells
mixed with 20 ll aPTT reagent (MDC Hemostasis, Germany) and
50 ll fresh frozen normal human plasma. After incubation for
15 min at 37 C, 20 ll of 50 mM CaCl2 was added to each well to
initiate the clotting reaction. The clotting time was determined
by reading the absorbance at 630 nm wavelength using an
Elx808 kinetic microtiter reader (BioTek, USA). For the PT assay,
10 ll puriﬁed protein at various concentrations was mixed with
45 ll normal human plasma in microtiter wells. After incubating
for 15 min at 37 C, 45 ll PT reagent (MDC Hemostasis) was added.
The clotting time was determined by an Elx808 kinetic microtiter
reader as above.
2.6. Serine protease inhibition assays
The inhibitory activity of rAduNAP4 against serine proteases
was tested with chromogenic substrates in an in vitro assay.
Ten microliters puriﬁed protein at a ﬁnal concentration of
1 lM was incubated with 50 ll of each serine protease (ﬁnal
concentration 1 nM) (Haematologic Technologies Inc., USA) in
HBSAC buffer (50 mM HEPES, pH 7.4, 200 mM NaCl, 10 mM
CaCl2, 0.2% bovine serum albumin and 0.1% NaN3) for 15 min
at 25 C. After the addition of 40 ll of the corresponding chromo-
genic substrate (Chromogenix) to a ﬁnal concentration of
400 lM, the absorbance at 405 nm was recorded by an Elx808
kinetic microtiter reader. In this study, S2765 was used as the
substrate for human fXa, S2288 was used for human a-thrombin,
human plasmin, fXIIa and kallikrein (BBI, Canada), S2366 was
used for human fXIa and human activated protein C. The inhib-
itory activity of rAduNAP4 against fVIIa/TF complex was deter-
mined as follows: 250 nM recombinant protein was incubated
with 100 nM soluble TF (Protgen, Beijing, China) and 10 nM re-
combinant fVIIa (Novo-Nordisk, Denmark) for 20 min at 25 C
with or without 100 nM EGR-fXa (Haematologic Technologies
Inc.). The residual fVIIa activity was measured with an Elx808 ki-
netic microtiter reader.
2.7. Kinetic analysis of fXa and fXIa inhibition
In each microtiter well, 10 ll of rAduNAP4 at different concen-
trations was incubated with 50 ll fXa or fXIa (ﬁnal concentration
1 nM) for 15 min at 25 C. After the addition of 40 ll substrate
S2765 (for fXa), or S2366 (for fXIa), the velocity (mA/min at
405 nm) of substrate hydrolysis in the presence and absence of
rAduNAP4 was measured with a kinetic microtiter reader. Dou-
ble-reciprocal plot analysis was used to verify the inhibition mech-
anism. Non-linear regression analysis was performed using
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) to deter-
mine the inhibition constant Ki values.3. Results
3.1. Cloning of the AduNAP4 cDNA sequences
The AduNAP4 cDNA sequence (GenBank accession no.
EU552548) contains an ORF of 315 bp encoding the precursor of
1978 W. Gan et al. / FEBS Letters 583 (2009) 1976–1980a 104 amino acid peptide (Fig. 1). The deduced amino acid se-
quence includes a signal peptide of 23 amino acid residues. The
mature AduNAP4 consists of 81 amino acids with a predicted
molecular weight of 9437.7 Da and a predicted pI of 4.67. A BLAST
search showed that a partial sequence, named AduNAP4 in the pat-
ent US 5866542, has been deposited in GenBank (accession no.
AAE03794). The amino acid sequence of AduNAP4 has high homol-
ogy with the NAPs from A. caninum and A. ceylanicum. The align-
ment of AduNAP4 amino acid sequence with other known NAPs
is shown in Fig. 2. The percentage similarities of AduNAP4 amino
acid sequence with AceAP1, AcAP5, AcAP6, AcAPc2, AcAPc3 and
AcAPc4 are 49.4%, 50.0%, 47.9%, 33.8%, 33.3%, and 31.6%,
respectively.
3.2. Expression and puriﬁcation of rAduNAP4
The mature AduNAP4 was expressed as a fusion with a N-termi-
nal thioredoxin and histidine tag after induction with 1 mM IPTG.
The rAduNAP4 fusion protein accumulated within the cells and
was found primarily in the soluble fraction.Fig. 1. Nucleotide sequence of the cDNA encoding AduNAP4. The predicted signal pept
sequence data had been deposited in GenBank (accession no. EU552548).
Fig. 2. Multiple-sequence alignment of mature AduNAP4 with that of known NAPs. The s
in brackets: AcAP5 (AAC47082), AcAP6 (AAC47081), AcAPc2 (AAC47080), AcAPc3 (AAP57
shaded in black. The length of each protein is indicated on the right.3.3. Effect of rAduNAP4 in human plasma clotting
The rAduNAP4 fusion protein showed extremely efﬁcient anti-
coagulant activity, whereas the protein contained the thioredoxin
and histidine tag alone has no anticoagulant activity. This sug-
gested that it is the AduNAP4 possessed the anticoagulant activity.
As shown in Fig. 3, rAduNAP4 prolonged the clotting time of nor-
mal human plasma in a concentration dependent manner. Dou-
bling time in the aPTT and PT occurred at estimated
concentrations of 23.1 nM and 154.9 nM, respectively.
3.4. Inhibitory activity of rAduNAP4 against fXa and fXIa
There was no inhibition of fXa and fXIa by the thioredoxin and
histidine tag alone. Whereas rAduNAP4 inhibited the catalytic
activity of fXa and fXIa. Double-reciprocal plot analysis showed
that AduNAP4 is a mixed - type inhibitor against fXa (Ki =
7.34 ± 1.74 nM), but a competitive inhibitor against fXIa
(Ki = 42.45 ± 3.25 nM) (Fig. 3). No inhibitory activity against throm-
bin, kallikrein, fXIIa, plasmin, activated protein C, or the fVIIa/TFide is underlined and the stop codon (TAA) is indicated by an asterisk. Nucleotide
equences are from GenBank and the accession number for each protein is indicated
305), AcAPc4 (AAP82926) and AceAP1 (AAK81733). Identical amino acid residues are
Fig. 3. Anticoagulant activities of AduNAP4. (A) Double-reciprocal plot indicative of mixed-type inhibition against fXa of AduNAP4. One nM of fXa was incubated with various
concentrations of S-2765 (0–800 lM) in the presence of rAduNAP4 at 0 nM (d), 8 nM (), 16 nM (j), 32 nM (N). (B) Concentration-dependent inhibition of fXa by rAduNAP4.
The ratio of velocities of substrate hydrolysis in the presence of rAduNAP4 (V) and the absence of rAduNAP4 (Vo) is plotted, showing the relative inhibition by the
recombinant protein. (C) Double-reciprocal plot indicative of competitive inhibition against fXIa of AduNAP4. fXIa (1nM) was incubated with various concentrations of S-
2366 (0–800 lM) in the presence of rAduNAP4 at 0 nM (d), 20 nM (), 40 nM (j), 80 nM (N). (D) Concentration-dependent inhibition of fXIa by rAduNAP4. The ratio of
velocities of substrate hydrolysis in the presence of rAduNAP4 (V) and the absence of rAduNAP4 (Vo) is plotted, showing the relative inhibition by the recombinant protein. (E)
Prolongation of the aPTT by rAduNAP4. The concentration required for doubling time the aPTT was estimated to be 23.1 nM. (F) Prolongation of the PT by rAduNAP4. The
concentration required for doubling time the PT was estimated to be 154.9 nM.
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rAduNAP4.
4. Discussion
Hookworm infection leading to anemia is caused by chronic
gastrointestinal blood loss. Hookworms secrete antihaemostatic
molecules to promote blood ﬂow and stop clot formation at the
feeding site [13–16]. Several anticoagulant peptides have been iso-
lated from A. caninum and A. ceylanicum. This study reports the
cloning and characterization of an anticoagulant peptide, named
AduNAP4, from the human hookworm A. duodenale.
Althoughmany anticoagulants including inhibitors of thrombin,
fXa, fVIIa/TF complexes, and fXIIa, and targets of tenase, prothrom-
binase, and the kallikrein–kinin system, have been found in blood-
feeding animals [10–12,18,19], no fXIa inhibitor has previously
been described for these animals. A previous study demonstrated
that puriﬁed AcAP from soluble A. caninum extract inhibited activ-
ity of fXIa by 55% at a 200-fold molar excess of inhibitor to enzyme,
and AcAP5 may be responsible for this inhibition of fXIa, but no
inhibitor of fXIa was detected at equimolar concentrations of
inhibitor to enzyme [13,20]. AduNAP4 as an anticoagulant peptide
from the human hookworm A. duodenale, inhibits both fXa and fXIa
with Ki = 7.34 ± 1.74 nM and 42.45 ± 3.25 nM, respectively. Signiﬁ-
cantly, fXIa plays an important role in the ampliﬁcation of the ini-
tial coagulation via a positive feedback mechanism for the
generation of additional thrombin. Our data suggests that the hu-
man hookworm A. duodenale interferes with the host coagulation
cascade by inhibition not only of the fXa but also the fXIa.
AduNAP4 proved extremely efﬁcient at prolonging the aPTT,
with a doubling time at an estimated concentration of 23.1 nM.
This compares with AcAP5 and AceAP1 with doubling times at esti-
mated concentrations of 560 pM and 73 nM, respectively [16].
However, AduNAP4 has lower afﬁnity with human factor Xa
(Ki = 7.34 ± 1.74 nM) than AcAP5 (Ki = 43 pM) and AceAP1
(Ki = 2 nM). The stronger anticoagulant activity of AduNAP4 com-
pared with AceAP1 might be caused partly by the fXIa inhibitory
activity of AduNAP4.In summary, we have identiﬁed and characterized an antico-
agulant peptide functioning as an inhibitor of both fXa and fXIa
from the human hookworm A. duodenale. These results provide
new insight into the mechanisms that counteract host hemostat-
ic responses in order to facilitate blood feeding by the
hookworm.Acknowledgments
This research was supported by a Grant from the Guangdong
Natural Science Foundation (No. 04011381), a Grant of YuMiao
Project from the Department of Education of Guangdong Province
(No. 08-NYM-062), and a Grant from Dongguan Science and Tech-
nology Planning Project, Guangdong Province, China (No.
2008108101038).
References
[1] Butenas, S. and Mann, K.G. (2002) Blood coagulation. Biochemistry (Mosc) 67,
3–12.
[2] Vine, A.K. (2009) Recent advances in haemostasis and thrombosis. Retina 29,
1–7.
[3] von dem Borne, P.A., Cox, L.M. and Bouma, B.N. (2006) Factor XI enhances
ﬁbrin generation and inhibits ﬁbrinolysis in a coagulation model initiated by
surface-coated tissue factor. Blood Coagul. Fibrinolysis 17, 251–257.
[4] Wang, Z.Y., Wang, X.Z., Peng, Y.F., Hu, X.S., Feng, R.Y., Wang, H.T. and Lin, F.Q.
(1983) Blood sucking activities of hookworms. Routes and quantities of blood
loss in Ancylostoma caninum, A. duodenale and A. ceylanicum infections. Chin.
Med. J. (Engl.) 96, 281–286.
[5] Roche, M. and Layrisse, M. (1966) The nature and causes of hookworm anemia.
Am. J. Trop. Med. Hyg. 15, 1029–1102.
[6] Crompton, D.W. (2000) The public health importance of hookworm disease.
Parasitology 121, S39–S50.
[7] Hotez, P., Brooker, J.S., Bethony, J.M., Bottazzi, M.E., Loukas, A. and Xiao, S.
(2004) Hookworm infection. New Engl. J. Med. 351, 799–807.
[8] de Silva, N.R., Brooker, S., Hotez, P.J., Montresor, A., Engels, D. and Savioli, L.
(2003) Soil-transmitted helminth infections: updating the global picture.
Trends Parasitol. 19, 547–551.
[9] Hotez, P.J., Bethony, J., Bottazzi, M.E., Brooker, S., Diemert, D. and Loukas, A.
(2006) ) New technologies for the control of human hookworm infection.
Trends Parasitol. 22, 327–331.
[10] Salzet, M. (2001) Anticoagulants and inhibitors of platelet aggregation derived
from leeches. FEBS Lett. 492, 187–192.
1980 W. Gan et al. / FEBS Letters 583 (2009) 1976–1980[11] Maritz-Olivier, C., Stutzer, C., Jongejan, F., Neitz, A.W. and Gaspar, A.R. (2007)
Tick anti-hemostatics: targets for future vaccines and therapeutics. Trends
Parasitol. 23, 397–407.
[12] Champagne, D.E. (2004) Antihemostatic strategies of blood-feeding
arthropods. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4, 375–
396.
[13] Stassens, P., Bergum, P.W., Gansemans, Y., Jespers, L., Laroche, Y., Huang, S.,
Maki, S., Messens, J., Lauwereys, M., Cappello, M., Hotez, P.J., Lasters, I. and
Vlasuk, G.P. (1996) Anticoagulant repertoire of the hookworm Ancylostoma
caninum. Proc. Natl. Acad. Sci. USA 93, 2149–2154.
[14] Mieszczanek, J., Harrison, L.M., Vlasuk, G.P. and Cappello, M. (2004)
Anticoagulant peptides from Ancylostoma caninum are immunologically
distinct and localize to separate structures within the adult hookworm. Mol.
Biochem. Parasitol. 133, 319–323.
[15] Del Valle, A., Jones, B.F., Harrison, L.M., Chadderdon, R.C. and Cappello, M.
(2003) Isolation and molecular cloning of a secreted hookworm platelet
inhibitor from adult Ancylostoma caninum. Mol. Biochem. Parasitol. 129, 167–
177.[16] Harrison, L.M., Nerlinger, A., Bungiro, R.D., Córdova, J.L., Kuzmic, P. and
Cappello, M. (2002) Molecular characterization of Ancylostoma inhibitors of
coagulation factor Xa. Hookworm anticoagulant activity in vitro predicts
parasite bloodfeeding in vivo. J. Biol. Chem. 277, 6223–6629.
[17] Mieszczanek, J., Harrison, L.M. and Cappello, M. (2004) Ancylostoma
ceylanicum anticoagulant peptide-1: role of the predicted reactive site
amino acid in mediating inhibition of coagulation factors Xa and VIIa. Mol.
Biochem. Parasitol. 137, 151–159.
[18] Campos, I.T., Tanaka-Azevedo, A.M. and Tanaka, A.S. (2004) Identiﬁcation and
characterization of a novel factor XIIa inhibitor in the hematophagous insect,
Triatoma infestans (Hemiptera: Reduviidae). FEBS Lett. 577, 512–516.
[19] Isawa, H., Orito, Y., Jingushi, N., Iwanaga, S., Morita, A., Chinzei, Y. and Yuda, M.
(2007) Identiﬁcation and characterization of plasma kallikrein–kinin system
inhibitors from salivary glands of the blood-sucking insect Triatoma infestans.
FEBS J. 274, 4271–4286.
[20] Cappello, M., Vlasuk, G.P., Bergum, P.W., Huang, S. and Hotez, P.J. (1995)
Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of
human coagulation factor Xa. Proc. Natl. Acad. Sci. USA 92, 6152–6156.
